9781032291680 - biopharmaceutical informatics: learning to discover developable biotherapeutics (15 resultados)
- Tapa blanda
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de AmericaGreatBookPrices
Contactar con el vendedorVendedor de 5 estrellasCondición: Usado - Como Nuevo
EUR 71,89
Envío por EUR 2,31Se envía dentro de Estados Unidos de AmericaCantidad disponible: 10 disponibles
Condición: As New. Unread book in perfect condition.
- Tapa blanda
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de AmericaGreatBookPrices
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 75,15
Envío por EUR 2,31Se envía dentro de Estados Unidos de AmericaCantidad disponible: 10 disponibles
Condición: New.
- Tapa blanda
Librería: California Books, Miami, FL, Estados Unidos de AmericaCalifornia Books
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 77,54
Gastos de envío gratisSe envía dentro de Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Condición: New.
- Tapa blanda
Librería: Majestic Books, Hounslow, Reino UnidoMajestic Books
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 76,67
Envío por EUR 7,62Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 3 disponibles
Condición: New.
- Tapa blanda
Librería: PBShop.store UK, Fairford, GLOS, Reino UnidoPBShop.store UK
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 80,53
Envío por EUR 5,89Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
PAP. Condición: New. New Book. Shipped from UK. Established seller since 2000.
- Tapa blanda
Librería: GreatBookPricesUK, Woodford Green, Reino UnidoGreatBookPricesUK
Contactar con el vendedorVendedor de 5 estrellasCondición: Usado - Como Nuevo
EUR 72,88
Envío por EUR 17,59Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 10 disponibles
Condición: As New. Unread book in perfect condition.
- Tapa blanda
Librería: GreatBookPricesUK, Woodford Green, Reino UnidoGreatBookPricesUK
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 80,51
Envío por EUR 17,59Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 10 disponibles
Condición: New.
- Tapa blanda
Librería: Biblios, frankfurt am main, HESSE, AlemaniaBiblios
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 87,80
Envío por EUR 9,95Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 3 disponibles
Condición: New.
- Tapa blanda
Librería: Books Puddle, New York, NY, Estados Unidos de AmericaBooks Puddle
Contactar con el vendedorVendedor de 4 estrellasCondición: Nuevo
EUR 100,40
Envío por EUR 3,49Se envía dentro de Estados Unidos de AmericaCantidad disponible: 3 disponibles
Condición: New.
- Tapa blanda
Librería: Revaluation Books, Exeter, Reino UnidoRevaluation Books
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 103,10
Envío por EUR 14,66Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Paperback. Condición: Brand New. 368 pages. 6.14x0.80x9.21 inches. In Stock.
- Tapa blanda
Librería: moluna, Greven, Alemaniamoluna
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 79,46
Envío por EUR 48,99Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: Más de 20 disponibles
Condición: New. Dr. Sandeep Kumar is currently a Distinguished Fellow (Executive Director) at the department of Computational Science in Moderna Therapeutics, Cambridge, MA where he leads Molecular Design and Modeling team. Sandeep Kumar holds a Ph.D. in Computat.
- Tapa blanda
Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 107,27
Envío por EUR 63,55Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Taschenbuch. Condición: Neu. Neuware - Despite the phenomenal clinical success of antibody-based biopharmaceuticals in recent years, discovery and development of these novel biomedicines remains a costly, time-consuming, and risky endeavor with low probability of success. To bring better biomedicines to patients faster, we have…come up with a strategic vision of Biopharmaceutical Informatics which calls for syncretic use of computation and experiment at all stages of biologic drug discovery and pre-clinical development cycles to improve probability of successful clinical outcomes. Biopharmaceutical Informatics also encourages industry and academic scientists supporting various aspects of biotherapeutic drug discovery and development cycles to learn from our collective experiences of successes and, more importantly, failures. The insights gained from such learnings shall help us improve the rate of successful translation of drug discoveries into drug products available to clinicians and patients, reduce costs, and increase the speed of biologic drug discovery and development. Hopefully, the efficiencies gained from implementing such insights shall make novel biomedicines more affordable for patients.This unique volume describes ways to invent and commercialize biomedicines more efficiently: - Calls for digital transformation of biopharmaceutical industry by appropriately collecting, curating, and making available discovery and pre-clinical development project data using FAIR principles - Describes applications of artificial intelligence and machine learning (AIML) in discovery of antibodies in silico (DAbI) starting with antigen design, constructing inherently developable antibody libraries, finding hits, identifying lead candidates, and optimizing them - Details applications of AIML, physics-based computational design methods, and other bioinformatics tools in fields such as developability assessments, formulation and excipient design, analytical and bioprocess development, and pharmacology - Presents pharmacokinetics/pharmacodynamics (PK/PD) and Quantitative Systems Pharmacology (QSP) models for biopharmaceuticals - Describes uses of AIML in bispecific and multi-specific formats Dr Sandeep Kumar has also edited a collection of articles dedicated to this topic which can be found in the Taylor and Francis journal mAbs.
- Tapa blanda
- Impresión bajo demanda
Librería: Grand Eagle Retail, Bensenville, IL, Estados Unidos de AmericaGrand Eagle Retail
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 58,20
Gastos de envío gratisSe envía dentro de Estados Unidos de AmericaCantidad disponible: 1 disponibles
Paperback. Condición: new. Paperback. Despite the phenomenal clinical success of antibody-based biopharmaceuticals in recent years, discovery and development of these novel biomedicines remains a costly, time-consuming, and risky endeavor with low probability of success. To bring better biomedicines to patients faster, we have c…ome up with a strategic vision of Biopharmaceutical Informatics which calls for syncretic use of computation and experiment at all stages of biologic drug discovery and pre-clinical development cycles to improve probability of successful clinical outcomes. Biopharmaceutical Informatics also encourages industry and academic scientists supporting various aspects of biotherapeutic drug discovery and development cycles to learn from our collective experiences of successes and, more importantly, failures. The insights gained from such learnings shall help us improve the rate of successful translation of drug discoveries into drug products available to clinicians and patients, reduce costs, and increase the speed of biologic drug discovery and development. Hopefully, the efficiencies gained from implementing such insights shall make novel biomedicines more affordable for patients.This unique volume describes ways to invent and commercialize biomedicines more efficiently:Calls for digital transformation of biopharmaceutical industry by appropriately collecting, curating, and making available discovery and pre-clinical development project data using FAIR principlesDescribes applications of artificial intelligence and machine learning (AIML) in discovery of antibodies in silico (DAbI) starting with antigen design, constructing inherently developable antibody libraries, finding hits, identifying lead candidates, and optimizing themDetails applications of AIML, physics-based computational design methods, and other bioinformatics tools in fields such as developability assessments, formulation and excipient design, analytical and bioprocess development, and pharmacologyPresents pharmacokinetics/pharmacodynamics (PK/PD) and Quantitative Systems Pharmacology (QSP) models for biopharmaceuticalsDescribes uses of AIML in bispecific and multi-specific formatsDr Sandeep Kumar has also edited a collection of articles dedicated to this topic which can be found in the Taylor and Francis journal mAbs. This book describes ways to invent and commercialize biomedicines in a more time and cost-efficient manner. Failure to translate a discovery into a marketed drug denies us an opportunity to improve the lives of patients who do not have access to effective therapies. Here, the authors provide a greater understanding of biopharmaceutical informatics. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
- Tapa blanda
- Impresión bajo demanda
Librería: CitiRetail, Stevenage, Reino UnidoCitiRetail
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 56,76
Envío por EUR 43,39Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Paperback. Condición: new. Paperback. Despite the phenomenal clinical success of antibody-based biopharmaceuticals in recent years, discovery and development of these novel biomedicines remains a costly, time-consuming, and risky endeavor with low probability of success. To bring better biomedicines to patients faster, we have c…ome up with a strategic vision of Biopharmaceutical Informatics which calls for syncretic use of computation and experiment at all stages of biologic drug discovery and pre-clinical development cycles to improve probability of successful clinical outcomes. Biopharmaceutical Informatics also encourages industry and academic scientists supporting various aspects of biotherapeutic drug discovery and development cycles to learn from our collective experiences of successes and, more importantly, failures. The insights gained from such learnings shall help us improve the rate of successful translation of drug discoveries into drug products available to clinicians and patients, reduce costs, and increase the speed of biologic drug discovery and development. Hopefully, the efficiencies gained from implementing such insights shall make novel biomedicines more affordable for patients.This unique volume describes ways to invent and commercialize biomedicines more efficiently:Calls for digital transformation of biopharmaceutical industry by appropriately collecting, curating, and making available discovery and pre-clinical development project data using FAIR principlesDescribes applications of artificial intelligence and machine learning (AIML) in discovery of antibodies in silico (DAbI) starting with antigen design, constructing inherently developable antibody libraries, finding hits, identifying lead candidates, and optimizing themDetails applications of AIML, physics-based computational design methods, and other bioinformatics tools in fields such as developability assessments, formulation and excipient design, analytical and bioprocess development, and pharmacologyPresents pharmacokinetics/pharmacodynamics (PK/PD) and Quantitative Systems Pharmacology (QSP) models for biopharmaceuticalsDescribes uses of AIML in bispecific and multi-specific formatsDr Sandeep Kumar has also edited a collection of articles dedicated to this topic which can be found in the Taylor and Francis journal mAbs. This book describes ways to invent and commercialize biomedicines in a more time and cost-efficient manner. Failure to translate a discovery into a marketed drug denies us an opportunity to improve the lives of patients who do not have access to effective therapies. Here, the authors provide a greater understanding of biopharmaceutical informatics. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
- Tapa blanda
- Impresión bajo demanda
Librería: AussieBookSeller, Truganina, VIC, AustraliaAussieBookSeller
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 91,95
Envío por EUR 32,39Se envía de Australia a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Paperback. Condición: new. Paperback. Despite the phenomenal clinical success of antibody-based biopharmaceuticals in recent years, discovery and development of these novel biomedicines remains a costly, time-consuming, and risky endeavor with low probability of success. To bring better biomedicines to patients faster, we have c…ome up with a strategic vision of Biopharmaceutical Informatics which calls for syncretic use of computation and experiment at all stages of biologic drug discovery and pre-clinical development cycles to improve probability of successful clinical outcomes. Biopharmaceutical Informatics also encourages industry and academic scientists supporting various aspects of biotherapeutic drug discovery and development cycles to learn from our collective experiences of successes and, more importantly, failures. The insights gained from such learnings shall help us improve the rate of successful translation of drug discoveries into drug products available to clinicians and patients, reduce costs, and increase the speed of biologic drug discovery and development. Hopefully, the efficiencies gained from implementing such insights shall make novel biomedicines more affordable for patients.This unique volume describes ways to invent and commercialize biomedicines more efficiently:Calls for digital transformation of biopharmaceutical industry by appropriately collecting, curating, and making available discovery and pre-clinical development project data using FAIR principlesDescribes applications of artificial intelligence and machine learning (AIML) in discovery of antibodies in silico (DAbI) starting with antigen design, constructing inherently developable antibody libraries, finding hits, identifying lead candidates, and optimizing themDetails applications of AIML, physics-based computational design methods, and other bioinformatics tools in fields such as developability assessments, formulation and excipient design, analytical and bioprocess development, and pharmacologyPresents pharmacokinetics/pharmacodynamics (PK/PD) and Quantitative Systems Pharmacology (QSP) models for biopharmaceuticalsDescribes uses of AIML in bispecific and multi-specific formatsDr Sandeep Kumar has also edited a collection of articles dedicated to this topic which can be found in the Taylor and Francis journal mAbs. This book describes ways to invent and commercialize biomedicines in a more time and cost-efficient manner. Failure to translate a discovery into a marketed drug denies us an opportunity to improve the lives of patients who do not have access to effective therapies. Here, the authors provide a greater understanding of biopharmaceutical informatics. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
